Opinion
Video
Author(s):
The panel examines how resistance mutations influence the efficacy of subsequent treatment lines and delves into the process of selecting later-line therapies based on next-generation sequencing results.
The OncFive: Top Oncology Articles for the Week of 8/25
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
State of the Science Summit - Breast Cancer: Chaired by Christos Vaklavas, MD
Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer
CDK4/6 Inhibitors, ADCs, and PI3K Inhibitors Individualize HR+ Breast Cancer Management
NSABP B-51 Data Highlight Evolving Role of Radiation in Early-Stage Breast Cancer
Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma
Dr Seymour on the Role of Mutational Profiling in CLL
Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features
Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL